

FLOREXA- eflornithine hydrochloride cream **Pella Pharmaceuticals Co. Ltd**

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Florexa

Composition

Each 1 g contains: Eflornithine hydrochloride 139 mg.

Excipients: Cetareth-25, Cetostearyl alcohol, Lanolin, Glyceryl monostearate, mineral oil, Cetyl alcohol, Methyl Paraben, Emulsifying wax, Dimethicone, and Purified Water.

Properties

Florexa is a prescribed medication applied to the skin for the reduction of unwanted facial hair in women.

There are no studies examining the inhibition of the enzyme ornithine decarboxylase (ODC) in human skin following the application of topical eflornithine. However, there are studies in the literature that report the inhibition of ODC activity in skin following oral eflornithine. It is postulated that topical eflornithine hydrochloride irreversibly inhibits skin ODC activity. This enzyme is necessary in the synthesis of polyamines. Animal data indicate that inhibition of ornithine decarboxylase inhibits cell division and synthetic functions, which affect the rate of hair growth. Eflornithine hydrochloride Cream 13.9% has been shown to retard the rate of hair growth in non-clinical and clinical studies.

Indications

Florexa is indicated for the reduction of unwanted facial hair in women. **Florexa** has only been studied on the face and adjacent involved areas under the chin of affected individuals. Usage should be limited to these areas of involvement.

Contraindications

Eflornithine HCl is contraindicated in patients with a history of sensitivity to any components of the preparation.

Children less than 12 years of age shouldn't use **Florexa**.

Precautions

For external use only.

Transient stinging or burning may occur when applied to abraded or broken skin.

Pregnancy

Because there are no adequate and well-controlled studies in pregnant women, the risk / benefit ratio of using eflornithine HCl in women with unwanted facial hair who are pregnant should be weighed carefully with serious consideration for either not implementing or discontinuing use of **Florea**.

Lactation

It is not known whether or not eflornithine hydrochloride is excreted in human milk. Caution should be exercised when **Florea** is administered to a nursing woman.

Drug Interactions

It is not known if Eflornithine HCl has any interaction with other topically applied drug products.

Warnings

Discontinue use if hypersensitivity occurs.

Dosage and Administration

Apply a thin layer of **Florea**, to wanted areas of the face and adjacent involved areas under the chin and rub in thoroughly. Do not wash treated area for at least 4 hours. Use twice daily at least 8 hours apart or as directed by a physician. The patient should continue to use hair removal techniques as needed in conjunction with **Florea**. (**Florea** should be applied at least 5 minutes after hair removal.) Cosmetics or sunscreens may be applied over treated areas; you should wait a few minutes to allow the treatment to be absorbed.

Florea doesn't permanently remove hair or "cure" unwanted facial hair. It is not a depilatory. Your treatment program should include continuation of any hair removal technique you are currently using. **Florea** will help you manage your condition and improve your appearance.

Improvement in the condition occurs gradually. Don't be discouraged if you see no immediate improvement. Be patient. Improvement may be seen as early as 4 to 8 weeks of treatment. Improvement may take longer in some individuals. If no improvement is seen after 6 months of use; discontinue use.

Overdosage

Overdosage information is unavailable.

Side Effects

The following side effects have been reported
Acne, Pseudofolliculitis Barbae, Stinging Skin, Headache, Burning Skin, Dry Skin, Pruritus (itching), Erythema (redness), Tingling Skin, Dyspepsia, skin irritation, rash, alopecia,

dizziness, folliculitis, hair ingrown, facial edema, anorexia, nausea, asthenia, vertigo.

Storage

Store below 30 °C.

How supplied

30 g packs

THIS IS A MEDICAMENT

- Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
- Strictly follow the doctor's prescription, the method of use and the instruction of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you.

Do not repeat the same prescription without consulting your doctor.

- Keep medicament out of reach of children.

Primary Package



Eflornithine HCl 13.9%

EACH 10 CONTAINS:
• Eflornithine HCl (339mg)



Manufactured By:
Palla Pharmaceuticals Co. Ltd. Jordan
www.dermapharm.com.jo

Store below 30 °C.
Read enclosed leaflet before use.
Keep out of reach of children.

FOR TOPICAL USE ONLY

Secondary Package



FLOREXA

eflornithine hydrochloride cream

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:82160-125
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
EFLORNITHINE HYDROCHLORIDE (UNII: 4NH22NDW9H) (EFLORNITHINE - UNII:ZQN1G5V6SR)	EFLORNITHINE HYDROCHLORIDE ANHYDROUS	4170 mg in 30 g

Product Characteristics

Color	white	Score	
Shape		Size	
Flavor		Imprint Code	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:82160-125-01	1 in 1 CARTON	02/09/2012	
1		30 g in 1 TUBE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		02/09/2012	

Labeler - Pella Pharmaceuticals Co. Ltd (562370925)

Revised: 12/2023

Pella Pharmaceuticals Co. Ltd